Spanish biotech startup Allbiotech Biotechnologies has completed the first production run of its Genesys V1 bioreactor, a lower-cost alternative for precision fermentation research. The company aims to make bioreactor technology more accessible to food tech startups, research institutions, and universities by offering a system priced at one-third of the cost of traditional pharmaceutical bioreactors.
“We are thus eliminating the economic barrier to entry, democratizing the use of bioreactors without the need for large investments”
With a 1-liter glass vessel, integrated sensors, and five peristaltic pumps, Genesys V1 is designed for early-stage testing, process optimization, and scale-up research in food production.
Allbiotech was founded in 2024 with the goal of reducing the cost barrier associated with precision fermentation equipment. “A cost-optimized design, coupled with our experience in manufacturing high-tech equipment, has allowed us to realize a new generation of bioreactors. We are thus eliminating the economic barrier to entry, democratizing the use of bioreactors without the need for large investments,” said Pablo Goñi, founder of Allbiotech.
Addressing limitations of repurposed equipment
Existing solutions for food tech startups often involve repurposed pharmaceutical lab equipment, which can be costly and ill-suited to agri-food applications. By offering an affordable, food-focused alternative, Allbiotech targets early-stage companies and research labs working with alternative proteins, dairy replacements, and other fermentation-derived ingredients.
The launch follows Allbiotech’s first investment round, completed in January and led by Daniel Palacio of Tutti Food Group. Additional investors include Ibai Meoki (engineer and former handball player), innovation specialist Ignacio Hernández, Javier García (Wehl & Partner), Jaime Urcola (Sakana S. Coop), and several others. The funding will support increased production and commercialization, with a second production run planned for March.
Palacio stated, “It is an exciting challenge to support an entrepreneur as unique as Pablo, with great experience in the world of technology, in the mission of promoting the research and development of new ingredients through precision fermentation.
Scaling through direct-to-consumer sales
Allbiotech plans to scale its operations by leveraging a direct-to-consumer sales model, similar to the approach used by Goñi’s other company, Noxon, which specializes in audiovisual equipment. This strategy will allow the company to bypass traditional distributors, reaching food tech startups and research teams through digital sales channels.
“Precision fermentation is increasingly used in food production, in a sustainable way and reducing CO₂ levels on our planet,” Palacio concluded.
